NAUT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAUT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Nautilus Biotechnology's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Nautilus Biotechnology's Operating Income for the three months ended in Mar. 2024 was $ -21.61 Mil. Nautilus Biotechnology's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate Nautilus Biotechnology's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Nautilus Biotechnology's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nautilus Biotechnology Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Interest Expense | - | - | - | - |
Nautilus Biotechnology Quarterly Data | ||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Interest Expense | Get a 7-Day Free Trial | - | - | - | - | - |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nautilus Biotechnology (NAS:NAUT) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Nautilus Biotechnology's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-21.61 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $29.95 Mil.
Nautilus Biotechnology's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
GuruFocus does not calculate Nautilus Biotechnology's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Nautilus Biotechnology Inc has enough cash to cover all of its debt. Its financial situation is stable.
Michael Seth Altman | director | C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Subramanian Sankar | officer: Senior VP, Product Development | C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070 |
Gwen E Weld | officer: Chief People Officer | C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121 |
Anna Mowry | officer: CFO and Treasurer | C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070 |
Matthew B. Murphy | officer: General Counsel | C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109 |
Sujal M Patel | director, 10 percent owner, officer: CEO, President, and Secretary | C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121 |
Mary E. Godwin | officer: Senior VP, Operations | 3101 WESTERN AVENUE, SEATTLE WA 98121 |
Karen Akinsanya | director | SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | director | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Matthew L. Posard | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Matthew S Mcilwain | director | 1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104 |
Benjamin A Horowitz | 10 percent owner | 2865 SAND HILL ROAD #101, MENLO PARK CA 94025 |
Marc L Andreessen | 10 percent owner | C/O ARNOLD & PORTER LLP, 3 EMBARCADERO CENTER 7TH FLOOR, SAN FRANCISCO CA 94111 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 08-09-2022
By sperokesalga sperokesalga • 02-21-2023
By Don Li2 Don Li2 • 11-02-2021
By GuruFocusNews GuruFocusNews • 01-27-2022
By PurpleRose PurpleRose • 07-13-2022
By Marketwired • 07-11-2023
By GuruFocusNews GuruFocusNews • 04-12-2022
By Marketwired • 09-06-2023
By Ds*** Ds*** • 08-30-2022
By GuruFocus Research • 10-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.